دورية أكاديمية
Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options
| العنوان: | Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options |
|---|---|
| المؤلفون: | Jiromaru,Rina, Nakagawa,Takashi, Yasumatsu,Ryuji |
| بيانات النشر: | Dove Press |
| سنة النشر: | 2022 |
| المجموعة: | Dove Medical Press |
| مصطلحات موضوعية: | Cancer Management and Research |
| الوصف: | Rina Jiromaru,1 Takashi Nakagawa,1 Ryuji Yasumatsu2 1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 2Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Kindai University, Osaka, JapanCorrespondence: Ryuji Yasumatsu, Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Kindai University, 377-2 Onohigashi, Osaka, 589-0014, Japan, Tel +81-72-3660221, Fax +81-72-3682252, Email ryuji.yasumatsu@med.kindai.ac.jpAbstract: Nasopharyngeal carcinoma (NPC) has seen improved treatment outcomes and a decrease in incidence worldwide in recent years due to developments in medicine and improved public health. However, 70% of cases are still diagnosed at advanced stages and these advanced NPC cases show a poor prognosis. Reports on current and future treatment in advanced NPC are summarized. Chemoradiotherapy is the mainstay of treatment for advanced NPC. The administration of platinum agents as a concurrent drug and intensity modulated radiotherapy (IMRT) is the most appropriate irradiation method, and is associated with high local control rates. For induction and adjuvant chemotherapy, platinum-based two- or three-drug combination chemotherapy is recommended. The tumour volume, plasma Epstein-Barr virus (EBV)-DNA levels, and the tumour site are used to determine the indication for adjuvant and neo-adjuvant chemotherapy. The tolerability of induction chemotherapy is controversial, and the indications and timing should be carefully considered in each case. Chemotherapy is used for patients with distant metastasis. Gemcitabine/cisplatin is the first-line regimen. The efficacy of immune checkpoint inhibitor (ICI) treatment has recently been reported for NPC and, as in other areas of the head and neck, it is expected to be effective for patients with recurrent/distant metastasis. Trials are underway for various uses of ICIs, including induction chemotherapy, postoperative treatment, and use in combination with ... |
| نوع الوثيقة: | article in journal/newspaper review |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | https://www.dovepress.com/advanced-nasopharyngeal-carcinoma-current-and-emerging-treatment-optio-peer-reviewed-fulltext-article-CMARTest |
| الإتاحة: | https://doi.org/10.2147/CMAR.S341472Test https://www.dovepress.com/advanced-nasopharyngeal-carcinoma-current-and-emerging-treatment-optio-peer-reviewed-fulltext-article-CMARTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.4AFEAA3A |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |